Pharmacokinetics and Tissue Distribution of $^{13}$C-Labeled Succinic Acid in Mice

Yonghwan Jung $^{1,2}$, Jin Sook Song $^1$ and Sunjoo Ahn $^{1,2,*}$

1 Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea
2 Department of Medicinal Chemistry and Pharmacology, Korea University of Science and Technology, Daejeon 34114, Republic of Korea
* Correspondence: sahn@krict.re.kr; Tel.: +82-42-860-7170

Abstract: Succinic acid is widely used as a food additive, and its effects on sepsis, cancer, ataxia, and obesity were recently reported. Dietary drug exposure studies have been conducted to evaluate the in vivo efficacy of succinic acid, but limited pharmacokinetic information is available. Therefore, this study evaluated the pharmacokinetic profiles and tissue distribution of succinic acid following a single intravenous or oral dose. A surrogate analyte, succinic acid-$^{13}$C$_4$ ($^{13}$C$_4$SA), was administered to distinguish endogenous and exogenous succinic acid. The concentration of $^{13}$C$_4$SA was determined by a validated analytical method using mass spectrometry. After a 10 mg/kg intravenous dose, non-compartmental pharmacokinetic analysis in plasma illustrated that the clearance, volume of distribution, and terminal half-life of $^{13}$C$_4$SA were 4574.5 mL/h/kg, 520.8 mL/kg, and 0.56 h, respectively. Oral $^{13}$C$_4$SA was absorbed and distributed quickly (bioavailability, 1.5%) at a dose of 100 mg/kg. In addition, $^{13}$C$_4$SA exposure was the highest in the liver, followed by brown adipose tissue, white adipose tissue, and the kidneys. This is the first report on the pharmacokinetics of succinic acid after a single dose in mice, and these results could provide a foundation for selecting dosing regimens for efficacy studies.

Keywords: succinic acid; LC-MSMS; tissue distribution; pharmacokinetics

1. Introduction

Succinic acid is an intermediate in the citric acid cycle, and its role in energy metabolism is well known. Systemic exposure to succinic acid induces Uncoupling protein 1-dependent thermogenesis, which ameliorates diet-induced obesity and improves glucose tolerance [1–3]. In addition, succinic acid has been proposed as a potential treatment for sepsis [4], hematopoiesis [5], and cancer [6–8] because of its ability to induce epigenetic changes through its receptor SUCNR1, a G protein-coupled receptor. Short-term exposure to succinic acid is also known to alleviate cerebellar mitochondrial oxidative phosphorylation dysfunction, neurodegeneration, and ataxia [9].

Despite the variety of pharmacological functions of succinic acid, no pharmacokinetic study following intravenous (IV) or oral (PO) administration has been reported. In general, the pharmacological efficacy of succinic acid has been evaluated by in vitro assays or in vivo studies using drinking water or food intake experiments [2,3,9]. In animal studies, it is difficult to evaluate the exact drug consumption for investigating pharmacokinetic/pharmacodynamics (PK/PD) correlations.

Therefore, we assessed the pharmacokinetic profile of succinic acid after a single IV or PO dose and evaluated its accumulation in the heart, liver, kidneys, brain, subcutaneous inguinal white adipose tissue (IWAT), and brown adipose tissue (BAT). To distinguish endogenous and exogenous succinic acid, stable isotope-labeled succinic acid-$^{13}$C$_4$ ($^{13}$C$_4$SA) was used, and its concentrations were analyzed using ultra high-performance liquid chromatography (UHPLC) with tandem mass spectrometry (MS/MS). Our results lay the
groundwork for future in vitro and in vivo studies of the pharmacological effects of succinic acid and provide a basis for selecting optimal dosing regimens for efficacy evaluations.

2. Materials and Methods

2.1. Chemicals and Reagents

$^{13}$C$_4$SA (>98%) and the internal standard (IS) citric acid-2,2,4,4-d$_4$ (CAD$_4$, >98%) were purchased from Cambridge Isotope Laboratories (Andover, MA, USA) and Toronto Research Chemicals (Toronto, ON, Canada), respectively. HPLC-grade methanol (MeOH), acetonitrile (ACN), and water were obtained from Honeywell Burdick & Jackson (Muskegon, MI, USA). Formic acid (99.0%) was purchased from Sam Chun (Pyeongtaek, Korea).

2.2. Calibration Standards and Quality Control (QC) Sample Preparation

The initial stock solutions of 1 mg/mL $^{13}$C$_4$SA and CAD$_4$ were prepared in MeOH. Calibration standard working solutions and QC working solutions were prepared in MeOH at concentrations ranging from 5 to 80,000 ng/mL. Calibration standards and QC samples were prepared by spiking the aforementioned working solutions with blank plasma or blank tissue homogenate.

2.3. Analytical Characterization

The concentrations of $^{13}$C$_4$SA in plasma and tissues were determined using a 1290 Infinity II series UHPLC system (Agilent Technologies, Palo Alto, CA, USA) coupled with an AB Sciex Qtrap 6500+ mass spectrometer (Concord, Canada). A Waters Atlantis Premier BEH C$_{18}$ AX column (2.1 × 100 mm, 1.7 µm particle size) was used, and the column temperature was maintained at 30 °C. The gradient mode consisted of mobile phases A (0.9% formic acid in water) and B (0.9% formic acid in ACN) as follows: 0–1.5 min (0%–0% B), 1.5–4.0 min (5%–30% B), 4.0–4.5 min (30%–30% B), 4.5–5.0 min (30%–0% B), and 5.0–5.5 min (0%–0% B). The flow rate was 0.3 mL/min. Meanwhile, 5-µL prepared samples were injected for analysis. The multiple reaction monitoring mode with negative electrospray ionization was used to quantify $^{13}$C$_4$SA and IS. The source temperature and ion spray voltage were 350 °C and −4500 kV, respectively. The ion source gas 1 flow pressure was 50 psig, and the gas 2 flow setting was 50 psig. The curtain gas pressure was 40 psig, and collision gas is medium. The optimized mass parameters for $^{13}$C$_4$SA and CAD$_4$ are listed in Table 1.

| Analytes | Precursor (m/z) | Production (m/z) | DP (Volts) | CE (Volts) | CXP (Volts) |
|----------|----------------|-----------------|------------|------------|-------------|
| $^{13}$C$_4$SA | 120.9 | 76.1 | −20 | −16 | −9 |
| CAD$_4$ | 194.9 | 114 | −5 | −18 | −13 |

2.4. Method Validation

The method was validated in terms of specificity, linearity, precision, accuracy, recovery, and matrix effects according to the Guidance for industry: Bioanalytical Method Validation by the Food and Drug Administration [10].

The specificity of the method was evaluated using blank mouse plasma or liver homogenate, $^{13}$C$_4$SA spiked plasma or liver homogenate, and plasma or liver samples after PO administration to exclude potential endogenous interference at the retention times of the analyte and IS.

Linearity was determined by plotting the peak area ratio (y) of samples to IS against the concentrations of the calibration standards (x). The equation was fitted by applying a weight factor of 1/x in linear regression analysis. The lower limit of quantification (LLOQ) was considered the lowest calibration standard, and it could be quantified reliably with acceptable precision of less than 20% and accuracy within ±20%.
The intra-day precision and accuracy of the method were confirmed by analyzing QC samples at three different concentrations five times on a single day, and the inter-day precision and accuracy were assessed by analyzing the QC samples over 3 consecutive days. For each concentration, five replicates were prepared. Relative standard deviation (RSD) and relative error (RE) were used to express the precision and accuracy, respectively.

The extraction recovery of analytes was assessed by comparing the peak area from five replicate QC samples at low, medium, and high concentrations that were spiked with analytes prior to extraction with the peak area of those that were spiked with blank biological samples. The matrix effects were evaluated by comparing the peak areas of the analytes in post-extracted blank biological samples spiked with QC samples with those of pure standard solutions with the same concentration that were dried directly and reconstituted with the mobile phase. These procedures were repeated for five replicates at three QC concentration levels.

2.5. Pharmacokinetic and Tissue Distribution Study

ICR mice (male, 30 ± 5 g, 7–8 weeks old) were obtained from Orient Bio Corporation (Sungnam, South Korea) and housed in an environmentally controlled room for 7 days of acclimatization. The mice were fasted overnight before the day of the experiment. The study was performed under the approval of the Korea Research Institute of Chemical Technology Animal Care and Use committee.

For the pharmacokinetic study, six mice were randomly assigned to two groups (three mice/group) and administered IV 10 mg/kg $^{13}$C$_4$SA or PO 100 mg/kg $^{13}$C$_4$SA. Blood samples were collected by a retro-orbital puncture at the following time points: 0.083, 0.5, 1, 2, 4, 8, and 24 h after IV administration and 0.25, 0.5, 1, 2, 4, 8, and 24 h after PO administration. After centrifugation (15,000 rpm for 3 min at 4 °C), 30-µL plasma samples were mixed with 120 µL of IS solution (500 ng/mL CAD$_4$ in 80% MeOH) for protein precipitation. After centrifugation (15,000 rpm for 10 min at 4 °C), 100 µL of the supernatant were transferred to a clean tube and evaporated to dryness in a centrifugal evaporator (EYELA CVE-3100, Tokyo, Japan). The residues were reconstituted with 100 µL of mobile phase A. The calibration samples were prepared by spiking different concentrations of $^{13}$C$_4$SA into the blank plasma.

For the tissue distribution analysis, mice received a single PO dose of 100 mg/kg $^{13}$C$_4$SA. After retro-orbital blood sample collection, the whole body was perfused with saline by placing the perfusion needle into the apex of the left ventricle and cutting the right atrium. Then, heart, liver, kidney, brain, IWAT, and BAT samples were collected and homogenized immediately with IS solution corresponding to three times the tissue weight. After centrifugation (15,000 rpm for 10 min at 4 °C), 120 µL of the tissue supernatant were transferred to a clean tube and evaporated to dryness in a centrifugal evaporator. The residues were reconstituted with 120 µL of the mobile phase. All biological samples filtered using 0.2-µm 96-well AcroPrep Advance filter plates (Pall Corporation, NY, USA) before analysis. Tissue standards covering the expected sample concentration range were made by spiking various concentration of $^{13}$C$_4$SA into the blank tissue homogenate.

The pharmacokinetic parameters of $^{13}$C$_4$SA in plasma were calculated using non-compartmental analysis using Phoenix WinNonlin software version 8.3.4 software. The maximum concentration ($C_{\text{max}}$) and time to peak concentration ($T_{\text{max}}$) were determined from the concentration–time curve. The terminal rate constant ($\lambda_z$) was calculated by linear regression of the logarithmic plasma concentration versus time curve. The elimination half-life ($T_{1/2}$) was calculated using $(\ln 2)/\lambda_z$. The area under the curve from the time of dosing to that of the last measurable concentration ($AUC_{\text{last}}$) and the area under the moment curve from the time of dosing to the last measurable concentration ($AUMC_{\text{last}}$) were determined using the linear trapezoidal method. The area under the curve from the time of dosing extrapolated to infinity ($AUC_{\infty}$) was defined as $AUC_{\text{last}} + (\text{the last measurable concentration} \times \lambda_z)$. The area under the first moment curve extrapolated to infinity ($AUMC_{\infty}$) was determined as $AUMC_{\text{last}} + \text{[time of last measurable observed concentration}$
\( (T_{\text{last}}) \times C_{\text{last}})/\lambda_z \) + \((C_{\text{last}}/\lambda_z^2)\). Clearance (CL) was estimated as \( \text{Dose}/\text{AUC}_{\infty} \). The mean residence time from the time of dosing to that of the last measurable concentration (MRT\(_{\text{last}}\)) and mean residence time extrapolated to infinity (MRT\(_{\infty}\)) were calculated as \( \text{AUMC}_{\text{last}}/\text{AUC}_{\text{last}} \) and \( \text{AUMC}_{\infty}/\text{AUC}_{\infty} \), respectively. Volume of distribution (\( V_{ss} \)) was calculated as \( \text{MRT}_{\infty} \times \text{CL} \). The absolute oral bioavailability (F) was calculated as \( (\text{AUC}_{\infty}^{\text{po}} \times \text{Dose}_{\text{iv}})/(\text{AUC}_{\infty}^{\text{iv}} \times \text{Dose}_{\text{po}}) \) \times 100.

3. Results
3.1. Method Validation

There was no significant interfering peak observed from endogenous substances in the biological samples at the retention times of \(^{13}\text{C}_4\text{SA}\) and IS. The typical chromatograms of \(^{13}\text{C}_4\text{SA}\) and IS were detected using an LC-MS/MS system, as presented in Figure 1.

![Figure 1. UHPLC-MS/MS chromatograms of \(^{13}\text{C}_4\text{SA}\) and \text{CAD}_4\) in plasma and liver samples: (A) blank matrix, (B) LLOQ concentration of spiked blank matrices with IS, and (C) samples (plasma and liver 15 min after PO administration of 100 mg/kg \(^{13}\text{C}_4\text{SA}\)).](image)

The regression equation and correlation coefficients (R) for \(^{13}\text{C}_4\text{SA}\) in different tissue homogenates and plasma are listed in Table 2.

The calibration curve of \(^{13}\text{C}_4\text{SA}\) in the biological samples exhibited good linearity with \( R \) exceeding 0.99. The intra- and inter-day precision and accuracy for \(^{13}\text{C}_4\text{SA}\) are presented in Table 3.
Table 2. Equations of $^{13}$C$_4$SA for quantification in plasma and different tissues in mice.

| Samples    | Standard Curve       | R     | Linear Range (ng/mL) | LLOQ (ng/mL) |
|------------|----------------------|-------|----------------------|--------------|
| Plasma     | 0.00096x + 0.000187  | 0.9999| 0.5–8000             | 0.5          |
| Heart      | 0.00255x – 0.00384   | 0.9984| 2.0–500              | 2            |
| Liver      | 0.00413x – 0.00356   | 0.9997| 0.5–2000             | 0.5          |
| Kidney     | 0.00270x – 0.00108   | 0.9982| 0.5–2000             | 0.5          |
| IWAT       | 0.00718x – 0.00590   | 0.9996| 2.0–2000             | 2            |
| BAT        | 0.00788x + 0.000207  | 0.9953| 0.5–2000             | 0.5          |
| Brain      | 0.00634x – 0.01420   | 0.9946| 2.0–2000             | 0.5          |

Table 3. Precision and accuracy of $^{13}$C$_4$SA in mouse plasma and tissues (mean ± SD, $n = 5$).

| Matrix | Concentration (ng/mL) | Intra-Day | Inter-Day |
|--------|-----------------------|-----------|-----------|
|        | Measured (ng/mL)      | Precision (RSD, %) | Accuracy (RE, %) | Measured (ng/mL) | Precision (RSD, %) | Accuracy (RE, %) |
| Plasma | 0.5       | 0.50 ± 0.04 | 8.1      | 2.8       | 0.48 ± 0.05 | 11.1    | −3          |
|        | 500       | 488.34 ± 6.10 | 1.3     | −2.3     | 511.24 ± 36.37 | 7.1      | 2.3         |
|        | 8000      | 7709.59 ± 527.79 | 6.9     | −3.6     | 7799.37 ± 332.90 | 4.3      | −2.5        |
| Heart  | 2         | 1.82 ± 0.08 | 4.4      | −6.6     | 1.84 ± 0.10 | 5.2      | −5.7        |
|        | 125       | 114.21 ± 9.71 | 8.5     | −8.6     | 121.17 ± 8.71 | 7.2      | −3.1        |
|        | 500       | 461.08 ± 36.01 | 7.8     | −7.8     | 490.41 ± 33.01 | 6.7      | −1.9        |
| Liver  | 0.5       | 0.47 ± 0.02 | 3.6      | −4.1     | 0.49 ± 0.04 | 9.2      | −0.2        |
|        | 125       | 126.27 ± 4.80 | 3.8     | 1        | 123.58 ± 6.47 | 5.2      | −1.1        |
|        | 2000      | 1971.52 ± 19.63 | 1       | −1.4     | 1946.28 ± 53.68 | 2.8      | −2.7        |
| Kidney | 0.5       | 0.54 ± 0.07 | 13       | 10.3     | 0.53 ± 0.07 | 12.8     | 8.4         |
|        | 125       | 121.17 ± 2.71 | 2.2     | −3.1     | 126.34 ± 7.75 | 6.1      | 1.1         |
|        | 2000      | 1902.34 ± 61.46 | 3.2     | −4.9     | 1946.28 ± 53.68 | 2.8      | −2.7        |
| IWAT   | 2         | 1.73 ± 0.13 | 7.5      | −11.4    | 1.83 ± 0.19 | 10.4     | −6.1        |
|        | 125       | 141.00 ± 6.66 | 4.7     | 12.8     | 132.63 ± 13.79 | 10.4     | 6.1         |
|        | 2000      | 2013.07 ± 63.04 | 3.1     | 0.7      | 1978.04 ± 50.92 | 2.6      | −1.1        |
| BAT    | 0.5       | 0.48 ± 0.07 | 14       | −1.4     | 0.53 ± 0.08 | 14.6     | 8.2         |
|        | 125       | 129.98 ± 6.78 | 5.2     | 4        | 126.34 ± 7.75 | 6.1      | 1.1         |
|        | 2000      | 2043.73 ± 116.20 | 5.7     | 2.2      | 1946.28 ± 53.68 | 2.8      | −2.7        |
| Brain  | 0.5       | 0.50 ± 0.07 | 14       | 2.2      | 0.48 ± 0.06 | 12.5     | −2.1        |
|        | 125       | 128.39 ± 7.93 | 6.2     | 2.7      | 128.23 ± 11.63 | 9.1      | 2.6         |
|        | 2000      | 2910.80 ± 55.73 | 2.9     | −4.5     | 1963.54 ± 65.03 | 3.3      | −1.8        |

RSD (%) = (standard deviation of the mean/mean) × 100; RE (%) = [(mean-theoretical concentration)/theoretical concentration] × 100.

RSD and RE were typically <15% for all analytes. These data demonstrate that the developed method was reliable and reproducible. The extraction recovery and matrix effect of $^{13}$C$_4$SA are presented in Table 4.

The extraction recoveries of each analyte at different concentrations were consistent, and a little ion suppression was observed in plasma, heart, and liver matrices. The RSD values at middle and high QC levels were <11.7% and the values were <15.5% at LLOQ QC levels in these matrices.
### Table 4. Recoveries and Matrix effects of $^{13}$C$_4$SA in mouse plasma and tissues (mean ± SD, $n = 5$).

| Matrix | Concentration (ng/mL) | Extraction Recovery (%) | Matrix Effect (%) |
|--------|------------------------|-------------------------|------------------|
| Plasma | 0.5                    | 89.4 ± 8.0              | 81.4 ± 8.6       |
|        | 500                    | 89.1 ± 7.2              | 97.9 ± 10.3      |
|        | 8000                   | 86.8 ± 3.9              | 86.8 ± 3.8       |
| Heart  | 2                      | 87.0 ± 14.2             | 88.0 ± 9.4       |
|        | 125                    | 104.7 ± 5.7             | 89.5 ± 6.2       |
|        | 500                    | 97.5 ± 3.1              | 84.3 ± 8.4       |
| Liver  | 0.5                    | 105.8 ± 9.2             | 85.2 ± 13.2      |
|        | 125                    | 98.5 ± 7.6              | 83.1 ± 6.2       |
|        | 2000                   | 90.7 ± 7.0              | 95.2 ± 9.2       |
| Kidney | 0.5                    | 113.5 ± 3.3             | 89.3 ± 4.0       |
|        | 125                    | 100.3 ± 9.5             | 94.9 ± 3.0       |
|        | 2000                   | 90.1 ± 2.5              | 95.0 ± 2.3       |
| IWAT   | 2                      | 86.6 ± 4.3              | 107.0 ± 2.3      |
|        | 125                    | 111.8 ± 8.5             | 95.3 ± 0.7       |
|        | 2000                   | 104.5 ± 4.5             | 106.1 ± 2.9      |
| BAT    | 0.5                    | 97.7 ± 12.8             | 95.2 ± 3.7       |
|        | 125                    | 106.7 ± 9.1             | 97.7 ± 1.5       |
|        | 2000                   | 91.3 ± 7.6              | 97.8 ± 6.8       |
| Brain  | 0.5                    | 95.1 ± 5.1              | 95.0 ± 11.1      |
|        | 125                    | 108.0 ± 12.1            | 99.6 ± 4.0       |
|        | 2000                   | 103.2 ± 10.4            | 90.7 ± 1.8       |

### 3.2. Pharmacokinetics Parameters

The plasma concentration–time profiles after IV injection of 10 mg/kg $^{13}$C$_4$SA and PO administration of 100 mg/kg $^{13}$C$_4$SA are presented in Figure 2, and the main pharmacokinetic parameters are listed in Table 5.

![Figure 2](image-url)
Table 5. $^{13}$C₄SA pharmacokinetic parameters in plasma (mean ± SD, n = 3).

| Pharmacokinetics Parameters | $^{13}$C₄SA (10 mg/kg) | $^{13}$C₄SA (100 mg/kg) |
|----------------------------|-------------------------|-------------------------|
| $T_{\text{max}}$ (h)       | 0.08                    | 0.25                    |
| $C_{\text{max}}$ (ng/mL)   | 6262.7 ± 994.9          | 6279.7 ± 33.5           |
| $T_{1/2}$ (h)              | 0.56 ± 0.09             | 0.83 ± 0.21             |
| AUC₄ₕ (ng·h/mL)            | 2222.8 ± 349.1          | 321.7 ± 60.6            |
| AUC∞ (ng·h/mL)             | 2223.8 ± 349.4          | 322.5 ± 60.3            |
| CL (mL/h/kg)               | 4574.5 ± 744.2          | NA                      |
| $V_{\text{ss}}$ (mL/kg)    | 520.8 ± 88.8            | NA                      |
| MRT₄ₕ (h)                  | 0.11 ± 0.01             | 0.44 ± 0.03             |
| MRT∞ (h)                   | 0.11 ± 0.01             | 0.45 ± 0.02             |
| F (%)                      | NA                      | 1.45                    |

NA (Not Applicable).

After IV administration (10 mg/kg), the plasma concentration of $^{13}$C₄SA in mice decreased rapidly in a biexponential manner with $T_{1/2}$ of 0.56 ± 0.09 h. CL of $^{13}$C₄SA was 4574.5 ± 744.2 mL/h/kg. $V_{\text{ss}}$ and MRT of $^{13}$C₄SA were 520.8 ± 88.8 mL/kg and 0.11 ± 0.01 h, respectively. After the PO administration of $^{13}$C₄SA, $T_{\text{max}}$ was 15 min with $C_{\text{max}}$ of 6297.7 ± 33.5 ng/mL, which indicated that $^{13}$C₄SA was rapidly absorbed. $^{13}$C₄SA was rapidly eliminated with $T_{1/2}$ of 0.83 ± 0.21 h. The AUC₄ₙₘ for PO and IV $^{13}$C₄SA were 321.7 ± 60.6 and 2222.8 ± 349.1, respectively. The calculated F of $^{13}$C₄SA was 1.5%. After IV and PO administration, the mean plasma concentration was below the LLOQ at the 4 h time point.

3.3. Tissue Distribution

The concentration–time profiles of tissues after a single PO dose of $^{13}$C₄SA (100 mg/kg) in mice are summarized in Table 6 and Figure 3.

Table 6. Concentration of $^{13}$C₄SA in plasma (ng/mL) and tissues (ng/g) after a single PO administration (100 mg/kg, mean ± SD, n = 3).

| Time (h) | Plasma | Heart | Liver | Kidney | IWAT | BAT | Brain |
|----------|--------|-------|-------|--------|------|-----|-------|
| 0.25     | 631.0 ± 99.4 | 44.5 ± 17.0 | 1167.6 ± 183.4 | 128.8 ± 47.5 | 149.0 ± 29.3 | 244.8 ± 68.6 | 11.6 ± 0.8 |
| 0.5      | 480.7 ± 45.1 | 13.6 ± 2.9 | 360.2 ± 129.8 | 54.5 ± 11.9 | 56.9 ± 24.6 | 80.3 ± 37.4 | 13.3 ± 0.1 |
| 1        | 46.5 ± 55.6  | BQL   | 78.9 ± 11.4 | 19.7 ± 22.2 | 37.1 ± 21.6 | 20.7 ± 14.0 | 13.2 ± 1.6 |
| 2        | 3.1 ± 0.2    | BQL   | 18.3 ± 9.0  | 18.9 ± 10.7 | 15.5 ± 3.2 | 8.7 ± 3.8 | 11.7 ± 1.6 |
| 4        | 0.7 ± 0.2    | BQL   | 15.3 ± 11.6 | 6.5 ± 1.4  | 14.9 ± 0.1 | 5.0 ± 3.2 | 9.6 ± 0.1 |
| 8        | BQL          | 4.3 ± 1.8 | 4.4 ± 1.1  | 12.9 ± 4.79 | 2.4 ± 1.2 | 9.2 ± 0.3 |
| 24       | BQL          | 2.3 ± 0.4 | 2.9 ± 1.1  | BQL     | BQL   | 9.6 ± 0.1 |

BQL (Below the Limit of Quantification).

Following PO administration, $^{13}$C₄SA was distributed rapidly in various tissues in mice. $T_{\text{max}}$ of $^{13}$C₄SA in most tissues was 15 min. The highest $C_{\text{max}}$ was observed in the liver (1167.6 ± 183.4 ng/g), followed by BAT (244.8 ± 68.6 ng/g), IWAT (149.0 ± 29.3 ng/g), the kidneys (128.8 ± 47.5 ng/g), the heart (44.5 ± 17.0 ng/g), and the brain (13.3 ± 0.1 ng/g).
To the best of our knowledge, this is the first PK study after a single IV and PO dose of succinic acid. However, it is challenging to accurately measure the drug dose in dietary exposure studies. The difficulty in obtaining accurate food intake records has been considered a “fundamental flaw” in human obesity studies [11]. The level of drug exposure is critical for interpreting concentration-dependent drug efficacy, and thus, systemic or target-specific PK/PD analysis can support the optimization of dosing regimens. Therefore, in the present study, the PK profile and tissue distribution of succinic acid were evaluated.

The first step of this research was developing a rapid and efficient analysis method for the quantitative determination of $^{13}$C$_4$SA. The validated UPLC-MS/MS method required a simple sample preparation procedure and presented good sensitivity (LLOQ < 2 ng/mL) in the biosamples, including mouse plasma and tissues, with a short run time.

To investigate the pharmacokinetic profile of succinic acid, $^{13}$C$_4$SA was administered to ICR mice. The surrogate analyte approach was chosen because of the lack of available succinate-free biosamples in the in vivo study [2,12,13]. The pharmacokinetics of $^{13}$C$_4$SA in mice was characterized by high CL and low-to-moderate $V_{ss}$. After PO administration (100 mg/kg), $^{13}$C$_4$SA was absorbed rapidly and F of $^{13}$C$_4$SA was extremely low (1.5%) in mice under the assumption of linear pharmacokinetics. This might be attributable to poor gastrointestinal permeability and a significant first-pass effect. Further studies to investigate the primary mechanism responsible for the poor F of succinic acid will be conducted in the future.

Following PO administration (100 mg/kg) in mice, the tissues were collected and homogenized. Then, the concentration of $^{13}$C$_4$SA was examined in heart, liver, kidney, brain, IWAT, and BAT samples at seven different time points. $^{13}$C$_4$SA was rapidly distributed in all tissues in mice with $T_{\text{max}}$ of 0.25–0.5 h. $C_{\text{max}}$ of $^{13}$C$_4$SA was the highest in the liver (1167.6 ng/g), followed by BAT (244.8 ng/g), IWAT (149.0 ng/g), the kidneys (128.8 ng/g), and thus, systemic or target-specific PK/PD analysis can support the optimization of dosing regimens. Therefore, in the present study, the PK profile and tissue distribution of succinic acid were evaluated.

To the best of our knowledge, this is the first PK study after a single IV and PO dose of succinic acid in mice.

The first step of this research was developing a rapid and efficient analysis method for the quantitative determination of $^{13}$C$_4$SA. The validated UPLC-MS/MS method required a simple sample preparation procedure and presented good sensitivity (LLOQ < 2 ng/mL) in the biosamples, including mouse plasma and tissues, with a short run time.

To investigate the pharmacokinetic profile of succinic acid, $^{13}$C$_4$SA was administered to ICR mice. The surrogate analyte approach was chosen because of the lack of available succinate-free biosamples in the in vivo study [2,12,13]. The pharmacokinetics of $^{13}$C$_4$SA in mice was characterized by high CL and low-to-moderate $V_{ss}$. After PO administration (100 mg/kg), $^{13}$C$_4$SA was absorbed rapidly and F of $^{13}$C$_4$SA was extremely low (1.5%) in mice under the assumption of linear pharmacokinetics. This might be attributable to poor gastrointestinal permeability and a significant first-pass effect. Further studies to investigate the primary mechanism responsible for the poor F of succinic acid will be conducted in the future.

Following PO administration (100 mg/kg) in mice, the tissues were collected and homogenized. Then, the concentration of $^{13}$C$_4$SA was examined in heart, liver, kidney, brain, IWAT, and BAT samples at seven different time points. $^{13}$C$_4$SA was rapidly distributed in all tissues in mice with $T_{\text{max}}$ of 0.25–0.5 h. $C_{\text{max}}$ of $^{13}$C$_4$SA was the highest in the liver (1167.6 ng/g), followed by BAT (244.8 ng/g), IWAT (149.0 ng/g), the kidneys (128.8 ng/g), and thus, systemic or target-specific PK/PD analysis can support the optimization of dosing regimens. Therefore, in the present study, the PK profile and tissue distribution of succinic acid were evaluated.

To the best of our knowledge, this is the first PK study after a single IV and PO dose of succinic acid in mice.
and the heart (44.5 ng/mL). Drug exposure was lowest in the brain (C max < 15 ng/mL).

Interestingly, the low exposure was maintained until 24 h after administration, whereas it was eliminated in a multi-exponential manner within 24 h in all other tissues. This suggests that hydrophilic and charged succinic acid does not easily penetrate the blood–brain barrier and it is not metabolized or eliminated across the blood–brain barrier very well. Its accumulation in the brain might be attributable to the limited expression of transporters or exchangers to facilitate its transport. Further research to investigate the factors responsible for the accumulation of succinic acid in the brain might be valuable.

Recently, various therapeutic effects of succinic acid beyond its historical role as a respiratory substrate of the mitochondrial electron transport chain were suggested. However, most in vivo studies that evaluated its efficacy were conducted after drug treatment via dietary exposure, and there was no PK information available. Therefore, the PK profile of succinic acid in mice after a single dose could be beneficial for optimizing dosing regimens for efficacy studies. In addition, drug exposure information in various tissues will help to better understand the role of succinic acid in specific tissues and conduct PK/PD analysis to investigate its effect against specific targets.

**Author Contributions:** Conceptualization, S.A. and Y.J.; Data curation, Y.J.; Investigation, Y.J. and S.A.; Methodology, S.A. and Y.J.; Project administration, S.A.; Supervision, S.A. and J.S.S.; Writing—original draft, Y.J.; Writing—review & editing, S.A., Y.J. and J.S.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was performed under the approval of the Korea Research Institute of Chemical Technology Animal Care and Use committee (study protocol ID: 7B-M2).

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Data is contained within the article.

**Conflicts of Interest:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**References**

1. Wang, Z.; Wang, Q.A.; Liu, Y.; Jiang, L. Energy metabolism in brown adipose tissue. *FEBS J.* 2021, 288, 3647–3662. [CrossRef] [PubMed]
2. Mills, E.L.; Pierce, K.A.; Jedrychowski, M.P.; Garrity, R.; Winther, S.; Vidoni, S.; Yoneshiro, T.; Spinelli, J.B.; Lu, G.Z.; Kazak, L.; et al. Accumulation of succinate controls activation of adipose tissue thermogenesis. *Nature* 2018, 560, 102–106. [CrossRef] [PubMed]
3. Ives, S.J.; Zaleski, K.S.; Slocum, C.; Escudero, D.; Sheridan, C.; Legesse, S.; Vidal, K.; Lagalwar, S.; Reynolds, T.H. The effect of succinic acid on the metabolic profile in high-fat diet-induced obesity and insulin resistance. *Physiol. Rep.* 2020, 8, e14630. [CrossRef] [PubMed]
4. Liu, H.; Zhang, H.; Zhang, X.; Chen, Q.; Xia, L. Role of succinic acid in the regulation of sepsis. *Int. Immunopharmacol.* 2022, 110, 109065. [CrossRef] [PubMed]
5. Hakak, Y.; Lehmann-Bruinsma, K.; Phillips, S.; Le, T.; Liaw, C.; Connolly, D.T.; Behan, D.P. The role of the GPR91 ligand succinate in hematopoiesis. *J. Leukoc. Biol.* 2009, 85, 837–843. [CrossRef] [PubMed]
6. Kasarci, G.; Ertugrul, B.; Iplik, E.S.; Cakmakoglu, B. The apoptotic efficacy of succinic acid on renal cancer cell lines. *Med. Oncol.* 2021, 38, 144. [CrossRef] [PubMed]
7. Iplik, E.S.; Catmakas, T.; Cakmakoglu, B. A new target for the treatment of endometrium cancer by succinic acid. *Cell. Mol. Biol.* 2018, 64, 60–63. [CrossRef] [PubMed]
8. Ertugrul, B.; Iplik, E.S.; Cakmakoglu, B. In Vitro Inhibitory Effect of Succinic Acid on T-Cell Acute Lymphoblastic Leukemia Cell Lines. *Arch. Med. Res.* 2021, 52, 270–276. [CrossRef] [PubMed]
9. Ferro, A.; Carbone, E.; Zhang, J.; Marzouk, E.; Villegas, M.; Siegel, A.; Nguyen, D.; Possidente, T.; Hartman, J.; Polley, K.; et al. Short-term succinic acid treatment mitigates cerebellar mitochondrial OXPHOS dysfunction, neurodegeneration and ataxia in a Purkinje-specific spinocerebellar ataxia type 1 (SCA1) mouse model. *PLoS ONE* 2017, 12, e0188425. [CrossRef] [PubMed]
10. Guidance for Industry, Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CMV). 2018. Available online: https://www.fda.gov/downloads/drugs/guidances/ucm070107.pdf (accessed on 24 May 2021).
11. Winkler, J.T. The fundamental flaw in obesity research. *Obes. Rev.* 2005, 6, 199–202. [CrossRef] [PubMed]
12. Tannahill, G.M.; Curtis, A.M.; Adamik, J.; Palsson-McDermott, E.M.; McGettrick, A.F.; Goel, G.; Frezza, C.; Bernard, N.J.; Kelly, B.; Foley, N.H.; et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. *Nature* **2013**, *496*, 238–242. [CrossRef] [PubMed]

13. Hass, D.T.; Bisbach, C.M.; Robbings, B.M.; Sadilek, M.; Sweet, I.R.; Hurley, J.B. Succinate metabolism in the retinal pigment epithelium uncouples respiration from ATP synthesis. *Cell Rep.* **2022**, *39*, 110917. [CrossRef] [PubMed]